Peptide Profiles — 2026-05-19
CJC-1295 + Ipamorelin is the single most-studied growth hormone (GH) secretagogue stack in current peptide research. Search interest for the combination has roughly doubled every year since 2022, and it now anchors the "GH research stack" category the way GP-1 agonists anchor metabolic research. This article is the plain-language explanation of what it is, why the two peptides are combined, and what the published research actually shows.
Code WELCOME at checkout unlocks 35% off the co-formulated CJC + Ipamorelin 10mg vial, standalone CJC-1295 (no DAC) 10mg, standalone Ipamorelin 10mg, the Bulk Stack (CJC + Ipa pairing), and bacteriostatic water for reconstitution. Every vial ships with a batch-matched Certificate of Analysis showing 99%+ HPLC purity.
CJC-1295 + Ipamorelin is a research peptide blend of two short-chain peptides that signal the pituitary gland to release more of the body's own growth hormone. They are combined because each peptide works on a different receptor and the two signals amplify each other — the combined GH pulse is roughly 3–5× larger than either peptide produces alone.
It is not synthetic HGH. The peptides do not contain growth hormone. They prompt the body to produce more of its own GH in a natural pulsatile pattern, which is mechanistically different from injecting recombinant human GH directly. (For the direct comparison, see CJC-1295 + Ipamorelin vs HGH.)
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) — the hormone the hypothalamus naturally releases to tell the pituitary "release more GH."
There are two versions of CJC-1295 in research catalogs, and the difference matters:
When you see "CJC-1295 + Ipamorelin" in a research protocol, assume it means the no-DAC version unless explicitly stated otherwise. For the full mechanism, see CJC-1295: Growth Hormone Research and Applications.
Ipamorelin is a pentapeptide (five amino acids) belonging to a class called growth hormone releasing peptides (GHRPs). Unlike CJC-1295, it does not act on the GHRH receptor — it acts on the ghrelin / GHS-R receptor, which is a separate pathway that also triggers GH release.
Ipamorelin's defining feature is selectivity. Older GHRPs like GHRP-6 and GHRP-2 stimulate GH release but also raise cortisol, prolactin, and appetite. Ipamorelin produces a clean GH pulse with minimal effects on those other hormones. This is the reason it has largely replaced earlier GHRPs in research protocols.
For the deeper profile, see Ipamorelin: The Selective Growth Hormone Secretagogue.
The two peptides target different receptors that both trigger GH release. When you stimulate only one pathway, you get a moderate GH pulse. When you stimulate both at the same time, the pulses are not additive — they are synergistic.
| Approach | Approximate GH pulse magnitude |
| CJC-1295 alone | 1× baseline pulse |
| Ipamorelin alone | 1× baseline pulse |
| CJC-1295 + Ipamorelin together | 3–5× baseline pulse |
The combination also produces a more reproducible pulse — timing is more consistent and inter-subject variability is lower than with either peptide alone.
A second reason researchers combine the two: lower per-peptide dose for the same effect. Hitting a 3–5× GH pulse with one peptide alone would require very high doses and produce dose-dependent side effects. Hitting the same pulse with the combination uses 100–300 mcg of each — well within the clean side-effect window.
Research applications for the CJC + Ipamorelin stack fall into four main buckets:
Three common SKUs in research catalogs:
| Product | What it contains |
| CJC-1295 + Ipamorelin 10mg blend | Pre-mixed vial with 5mg of each peptide. One injection = both peptides. The standard SKU. |
| CJC-1295 (no DAC) 10mg standalone | Single-peptide vial. Used when researchers want to dose the two peptides on different timelines, or when testing CJC mechanism alone. |
| Ipamorelin 10mg standalone | Single-peptide vial. Used the same way as above, or when stacking Ipamorelin with a different GHRH analog (such as tesamorelin). |
For most research protocols, the co-formulated blend is the practical choice — one injection per dose vs. two, lower cost per pulse, simpler reconstitution.
All three SKUs ship lyophilized (freeze-dried). They are activated by adding bacteriostatic water.
For the 10mg co-formulated vial: - Add 2 mL bacteriostatic water → final concentration 5 mg/mL combined (2.5 mg/mL of each peptide) - A 300/300 mcg dose = 0.12 mL = 12 units on a U-100 insulin syringe
For the full reconstitution math, dosing schedules, and protocol patterns, see the CJC-1295 + Ipamorelin Dosing Guide and the general peptide reconstitution guide.
The most commonly cited research protocol:
This is the protocol that anchors almost all of the published research and is the baseline that most researchers run before exploring more aggressive twice-daily or three-times-daily protocols.
Ipamorelin's selectivity is the reason the stack has a cleaner side-effect profile than older GHRP combinations. The main reported effects are dose-dependent fluid retention, occasional injection-site reactions, mild and transient appetite increase, and vivid dreams (a consequence of consolidated sleep architecture, not a problem). For the complete safety breakdown, see CJC-1295 + Ipamorelin Side Effects and Safety Profile.
Is it the same as taking HGH? No. HGH is the hormone itself. CJC + Ipa prompts the body to release more of its own GH in a natural pattern. The downstream effects overlap, but the mechanism, side-effect profile, cost, and pulsatility differ. See the full HGH comparison.
Should every researcher run it? No — it is a research-stack decision. The should-I-take-it guide walks through the decision framework.
How fast does it work? Sleep effects within 1–2 weeks. Body-composition effects across 8+ weeks. Full timeline in the results timeline article.
For a 12-week CJC + Ipa research protocol at 200/200 mcg daily:
Code WELCOME at checkout unlocks 35% off the co-formulated CJC + Ipa 10mg blend, standalone CJC-1295 (no DAC), standalone Ipamorelin, the Bulk Stack, the Shred & Bulk Stack (full recomp protocol), and bacteriostatic water. Every vial ships with a batch-matched COA showing 99%+ HPLC purity and US-based handling — the consistency required for endpoint-driven research over multi-month protocols.
Disclaimer: All information presented in this article is for educational and informational purposes only. Platinum Biolabs does not promote or endorse the use of peptides for human consumption. All products sold by Platinum Biolabs are intended strictly for laboratory and research use only. Consult a qualified healthcare professional before making any health-related decisions.